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 Resumo 
 A maioria dos antidepressivos tem o potencial de causar 
lesão hepática, mesmo em doses terapêuticas. Contudo, 
a hepatite tóxica por antidepressivos é um evento raro. 
Não existe forma de prevenir a hepatite tóxica, mas a sua 
gravidade pode ser minimizada com o diagnóstico preco-
ce e a retirada antecipada do fármaco. Apresentamos um 
caso raro de um homem de 63 anos com insuficiência he-
pática aguda após 3 meses de terapêutica com trazodona 
e diazepam em doses terapêuticas, com necessidade de 
transplante hepático. Com este caso pretende-se alertar 
os clínicos para a possibilidade desta entidade e da neces-
sidade de monitorização regular das provas hepáticas em 
doentes sob tratamento com trazodona, de forma a pre-
venir morbilidade e mortalidade. 
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 Abstract 
 Most antidepressant agents have the potential to cause liver 
injury, even at therapeutic doses. Nevertheless, drug-in-
duced liver injury (DILI) from antidepressant agents is a rare 
event. There is no way to prevent idiopathic DILI, but the se-
verity of the reaction may be minimized with prompt recog-
nition and early withdrawal of the agent. We describe a rare 
case of a 63-year-old man presenting with acute liver failure 
after 3 months of trazodone and diazepam administration at 
normal therapeutic doses, requiring liver transplantation. 
This report should increase physicians’ awareness of this 
complication and call attention to the regular monitoring of 
liver tests in patients taking trazodone, in order to prevent 
life-threatening complications. 
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 Introduction 
 Trazodone is a second-generation, nontricyclic anti-
depressant that has been linked to rare cases of hepatic 
injury. The onset of injury is usually several months after 
continuous ingestion and the presentation pattern is 
commonly one of hepatocellular serum enzyme eleva-
tion, although cases with a shorter latency and with a 
mixed or cholestatic form have also been described  [1] . 
There is no way to prevent idiopathic drug-induced liver 
injury (DILI), but the severity of the reaction may be min-
imized with prompt recognition and early withdrawal of 
the agent. We describe a rare case of acute liver failure 
(ALF) after 3 months of trazodone and diazepam admin-
istration at normal therapeutic doses, requiring liver 
transplantation.
 Clinical Case 
 A 57-year-old man with no previous medical history was start-
ed on diazepam (5 mg/day) and trazodone (200 mg/day) for de-
pression. Three months later, he developed increased jaundice and 
was admitted. Laboratory test results included marked elevations 
in serum aminotransferase levels (ALT 4,638 U/L, AST 2,745 U/L), 
with increases in GGT (603 U/L), alkaline phosphatase (122 U/L), 
bilirubin levels (12.7 mg/dL), and international normalized ratio 
(1.84). His liver enzymes were known to be normal in the past. All 
medications were stopped. Over the next week, he developed en-
cephalopathy, his international normalized ratio (2.37) and biliru-
bin (25.2 mg/dL) increased, and his factor V fell (from 51 to 29%). 
He was transferred to a liver transplant center and was listed for 
urgent liver transplantation. Test results for hepatitis A, B, and C 
were negative, as were serologic tests for acute cytomegalovirus, 
herpes simplex, and Epstein-Barr virus infection. Iron and copper 
studies were normal and autoantibodies were negative. An abdom-
inal ultrasound ruled out biliary obstruction and occlusion of the 
liver vessels. A liver biopsy showed confluent necrosis involving 
most of the liver parenchyma, intrahepatic cholestasis, modest in-
flammation, and evidence of feathery degeneration and ballooning 
of hepatocytes in parenchyma, but no fat or fibrosis, compatible 
with toxic ALF ( Fig. 1 ). In order to evaluate the causality between 
liver manifestation and drug treatment, the Council for Interna-
tional Organizations of Medical Sciences/Roussel Uclaf Causality 
Assessment Method (CIOMS/RUCAM) scale has been used. The 
CIOMS/RUCAM scale indicated a “probable” relationship for tra-
zodone and a “possible” relationship for diazepam in causing hep-
atotoxicity. While the patient was waiting for liver transplantation, 
encephalopathy worsened requiring mechanical ventilation. He 
underwent liver transplantation 2 weeks after medication stoppage 
and he fully recovered.
a
b
c
 Fig. 1. Photomicrographs of liver biopsy in hematoxylin and eosin 
staining showing confluent necrosis involving most of the liver 
parenchyma ( a , magnification ×40), modest inflammation and ev-
idence of feathery degeneration and ballooning of hepatocytes in 
parenchyma ( b , ×400), and intrahepatic cholestasis ( c , ×400). 
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 Discussion 
 Trazodone- and diazepam-induced ALF diagnosis 
was supported by (1) the development of hepatocellular 
liver injury 3 months after the introduction of trazodone 
and diazepam, (2) hepatotoxicity as a known adverse side 
effect of each of the drugs, (3) liver biopsy findings, espe-
cially confluent necrosis with inflammatory activity, 
which is the most common pattern seen in idiosyncratic 
adverse drug reactions complicated with ALF  [2] , and (4) 
exclusion of other etiologies of liver injury. Furthermore, 
when we assessed the causality by the CIOMS/RUCAM 
scale for trazodone, the score was in the category of “pos-
sible” cause of liver injury.
 DILI is a well-recognized problem that accounts for up 
to 10% of all adverse drug reactions. Two main mecha-
nisms of DILI have been proposed: predictable injury (in-
trinsic hepatotoxins) and unpredictable injury (idiosyn-
cratic reactions). In our case, an idiosyncratic reaction is 
likely to be the case. A literature review revealed that both 
drugs have been known to be implicated in DILI. Trazo-
done may cause alteration of liver enzyme levels at nor-
mal doses, but elevations are usually modest and usually 
do not require dose modification or discontinuation. 
Rare instances of ALF and death from trazodone have 
been described. The onset of liver toxicity may occur a 
few days or months after drug ingestion and even after the 
drug has been stopped. The pattern of liver injury is usu-
ally hepatocellular, but mixed or cholestatic forms have 
also been described. Contrarily, increases in liver en-
zymes during therapy with diazepam are rare and signif-
icant hepatotoxicity is uncommon. Only a few cases have 
been reported and none developed ALF  [3] . The onset of 
injury has ranged from 1 to 6 months, and the pattern of 
serum enzyme elevations has typically been cholestatic or 
mixed  [3] . The mechanism by which trazodone causes 
liver damage is unknown. Liver injury from benzodiaze-
pines is probably due to a rarely produced intermediate 
metabolite.
 This case is of special interest for its rarity. To our 
knowledge, only two other ALF cases associated with tra-
zodone have been reported. Hull et al.  [4] reported a 
72-year-old woman who developed ALT elevations (107 
U/L) 10 weeks after starting trazodone, trifluoperazine, 
and lithium, developing jaundice at 18 weeks and dying 2 
months later. Postmortem liver biopsy revealed acute he-
patic necrosis with cholestasis and portal inflammation 
 [4] . The second case occurred in a 48-year-old woman 
who developed fulminant liver failure after 4 months of 
trazodone and venlafaxine therapy, requiring liver trans-
plantation  [5] .
 This report should increase physicians’ awareness of 
this complication and call attention to the regular moni-
toring of liver tests in patients taking trazodone, especial-
ly if taken in concomitant therapy such as with other an-
tidepressants or antipsychotics, in order to prevent life-
threatening complications.
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